Currently, there are 205.10M common shares owned by the public and among those 150.62M shares have been available to trade.
The company’s stock has a 5-day price change of -6.74% and 35.64% over the past three months. HIMS shares are trading 148.88% year to date (YTD), with the 12-month market performance up to 165.59% higher. It has a 12-month low price of $5.65 and touched a high of $25.74 over the same period. HIMS has an average intraday trading volume of 9.38 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.10%, 34.76%, and 100.56% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Hims & Hers Health Inc (NYSE: HIMS) shares accounts for 47.18% of the company’s 205.10M shares outstanding.
It has a market capitalization of $4.76B and a beta (3y monthly) value of 1.09. The earnings-per-share (ttm) stands at -$0.02. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.77% over the week and 7.25% over the month.
Earnings per share for the fiscal year are expected to increase by 254.55%, and 159.05% over the next financial year.
Looking at the support for the HIMS, a number of firms have released research notes about the stock. Citigroup stated their Neutral rating for the stock in a research note on May 22, 2024, with the firm’s price target at $16-$20. Jefferies coverage for the Hims & Hers Health Inc (HIMS) stock in a research note released on April 16, 2024 offered a Hold rating with a price target of $15. Canaccord Genuity was of a view on April 10, 2024 that the stock is Buy, while Imperial Capital gave the stock Outperform rating on February 28, 2024, issuing a price target of $16. Leerink Partners on their part issued Market Perform rating on February 26, 2024.
